Abstract
Rituximab and infliximab are mAbs used in hematologic and autoimmune disease. Their use can be associated with hypersensitivity reactions (HSRs). Drug desensitization (DD) represents a therapeutic strategy to overcome HSRs.1 Although most DDs are completed successfully and safely, some can be complicated by breakthrough reactions, preventing further drug administration. We describe four patients who were treated with anti-IgE mAb omalizumab as part of DD in addition to premedication with montelukast (10 mg), famotidine (40 mg), chlorphenamine (10 mg), paracetamol (1,000 mg), and 6-methylprednisolone (40 mg), after we received approval from our ethical committee.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Allergy and Clinical Immunology: In Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
